Getting TRAIL back on track for cancer therapy

Systemic use of tumor necrosis factor alpha as an anticancer agent

(2015) Nicholas J. Roberts et al.   Oncotarget

TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells

(2014) Susann Voigt et al.   BMC CANCER

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity

(2014) H. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Necroptosis

(2014) Andreas Linkermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†

(2013) A. L. Cohn et al.   ANNALS OF ONCOLOGY

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer

(2013) Charles S. Fuchs et al.   CANCER

Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells

(2013) E Passante et al.   CELL DEATH AND DIFFERENTIATION

Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1

(2013) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family

(2013) K Azijli et al.   CELL DEATH AND DIFFERENTIATION

Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis

(2013) D Westphal et al.   CELL DEATH AND DIFFERENTIATION

Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death

(2013) Xin Chen et al.   CELL RESEARCH

Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancer--From Molecular Mechanism to Therapeutic Application

(2013) S. Fulda   CLINICAL CANCER RESEARCH

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

(2013) Zev A. Wainberg et al.   Clinical Colorectal Cancer

Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response

(2013) Michel DuPage et al.   CURRENT OPINION IN IMMUNOLOGY

Death receptor agonist therapies for cancer, which is the right TRAIL?

(2013) Pamela M. Holland   CYTOKINE & GROWTH FACTOR REVIEWS

Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells

(2013) Verena Haselmann et al.   GASTROENTEROLOGY

The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism

(2013) James M. Murphy et al.   IMMUNITY

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

(2013) Sunil Sharma et al.   INVESTIGATIONAL NEW DRUGS

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Luis Paz-Ares et al.   Journal of Thoracic Oncology

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer

(2013) Martin Reck et al.   LUNG CANCER

APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc  Receptors

(2013) C. Gieffers et al.   MOLECULAR CANCER THERAPEUTICS

Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis

(2013) Zhenyu Cai et al.   NATURE CELL BIOLOGY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Mechanisms of Action of Bcl-2 Family Proteins

(2013) A. Shamas-Din et al.   Cold Spring Harbor Perspectives in Biology

Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation

(2013) J. Silke et al.   Cold Spring Harbor Perspectives in Biology

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

(2013) Andres Forero-Torres et al.   Cancer Medicine

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth

(2012) Nicholas S. Wilson et al.   CANCER CELL

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

(2012) Caio M. Rocha Lima et al.   CANCER INVESTIGATION

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

(2012) Heather Huet et al.   CANCER RESEARCH

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation

(2012) S Jouan-Lanhouet et al.   CELL DEATH AND DIFFERENTIATION

Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?

(2012) L.H.A.M. de Wilt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

(2012) George D. Demetri et al.   EUROPEAN JOURNAL OF CANCER

Cellular FLICE-like inhibitory proteins (c-FLIPs): Fine-tuners of life and death decisions

(2012) Selcen Öztürk et al.   EXPERIMENTAL CELL RESEARCH

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients

(2012) Jochen Tuettenberg et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors

(2012) Melinda S. Merchant et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

(2012) V. Subbiah et al.   MOLECULAR CANCER THERAPEUTICS

A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death

(2012) Laura S. Dickens et al.   MOLECULAR CELL

Stoichiometry of the CD95 Death-Inducing Signaling Complex: Experimental and Modeling Evidence for a Death Effector Domain Chain Model

(2012) Kolja Schleich et al.   MOLECULAR CELL

TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer

(2012) Francois Gonzalvez et al.   MOLECULAR CELL

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

(2012) David L. Lacey et al.   NATURE REVIEWS DRUG DISCOVERY

ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells

(2012) S Cristofanon et al.   Cell Death & Disease

Recent advances in apoptosis, mitochondria and drug resistance in cancer cells

(2011) Inthrani R. Indran et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Caspase-8 and Bid: Caught in the act between death receptors and mitochondria

(2011) Chahrazade Kantari et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein

(2011) Guan Wang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms

(2011) Maria Feoktistova et al.   MOLECULAR CELL

Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis

(2011) Andrew Oberst et al.   NATURE

TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT

(2011) Najoua Lalaoui et al.   PLoS One

Molecular biology of Bax and Bak activation and action

(2010) Dana Westphal et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib

(2010) D Lecis et al.   BRITISH JOURNAL OF CANCER

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

(2010) Andres Forero-Torres et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

(2010) T. Doi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane

(2010) Z T Schug et al.   CELL DEATH AND DIFFERENTIATION

Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level

(2010) A Morizot et al.   CELL DEATH AND DIFFERENTIATION

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells

(2010) Frederik J.H. Hoogwater et al.   GASTROENTEROLOGY

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors

(2010) N. M. Haynes et al.   JOURNAL OF IMMUNOLOGY

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

(2010) Johannes Lemke et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Is TRAIL the holy grail of cancer therapy?

(2009) Thomas Newsom-Davis et al.   APOPTOSIS

Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family

(2009) Tobias Schilling et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2

(2009) Qian Yin et al.   BIOCHEMISTRY

Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling

(2009) Zhaoyu Jin et al.   CELL

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

TRAF2 Must Bind to Cellular Inhibitors of Apoptosis for Tumor Necrosis Factor (TNF) to Efficiently Activate NF-κB and to Prevent TNF-induced Apoptosis

(2009) James E. Vince et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The E3 Ubiquitin Ligase cIAP1 Binds and Ubiquitinates Caspase-3 and -7 via Unique Mechanisms at Distinct Steps in Their Processing

(2009) Young Eun Choi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment

(2009) Peter Geserick et al.   JOURNAL OF CELL BIOLOGY

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: It Does Not Always Fade With Time

(2009) Jean-Yves Douillard   JOURNAL OF CLINICAL ONCOLOGY

Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer

(2009) Tom M. Ganten et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

XIAP discriminates between type I and type II FAS-induced apoptosis

(2009) Philipp J. Jost et al.   NATURE

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance

(2008) M. Fakler et al.   BLOOD

BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer Cells

(2008) S. Huang et al.   CANCER RESEARCH

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

(2008) M Todaro et al.   CELL DEATH AND DIFFERENTIATION

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology

(2008) S WANG et al.   TRENDS IN PHARMACOLOGICAL SCIENCES